—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for AMRX, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sector × region Health care in US: −2.1% week · −2.2% month · +3.3% quarter · +16.4% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.84 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How AMRX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.84 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Amneal Pharmaceuticals, Inc. Class A Common Stock moved 0.84% on average · correlation 0.22 · higher than 80% of US names
  • Beta, last 3 months 0.22 less rate-sensitive lately than over the year
  • On the 10 worst bond days −1.23% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +2.46% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against AMRX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Amneal Pharmaceuticals, Inc. Class A Common Stock

AMRX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Amneal Pharmaceuticals develops, makes and distributes generic and specialty drugs, including injectables and biosimilars, from sites in the United States, India and Ireland. It groups its business into affordable generics, a specialty unit built around central nervous system and thyroid treatments such as Rytary and Unithroid, and a government-supply arm, AvKARE, that serves defence and veterans' health agencies. It sells through wholesalers, distributors, retail pharmacies and hospitals rather than direct to patients.
Where it sits in the stack
Amneal sits outside our AI build-out indices; it belongs to the healthcare sleeve of our universe, under specialty and generic drug manufacturing, with no seat in Rubin or Halo.
Who it is priced against
The diary has no peer group listed for Amneal in our data; the comparison the market draws is with other generic-drug makers such as Viatris.
Why Closelooknet tracks it
Amneal carries no index seat, no Closelooknet score and no quotes in our editions; coverage here rests only on its chart structure, not on any scored module.
What the diary watches
Whether the specialty segment's newer treatments, such as CREXONT, start to shift revenue away from the lower-margin generics business.

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 55/100 composite (momentum 91, quality 58, valuation 42) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Oppenheimer, 2026-09-23

The Street on this name

Analyst actions and the latest print for AMRX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Oppenheimer — target 27 Target set to $27 (+38.5% to spot) 2026-09-23

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What AMRX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +5.1% in FY2025 32 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)?

Amneal Pharmaceuticals, Inc. Class A Common Stock trades as AMRX on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is AMRX in a Closelooknet index?

Not currently — Amneal Pharmaceuticals, Inc. Class A Common Stock is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Closelooknet composite score?

55 out of 100, with momentum 91, quality 58 and valuation 42 sub-scores, as of 2026-10-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does AMRX trade against its moving averages?

Uptrend stack intact: Trades +10.2% vs the 50-day and +34.5% vs the 200-day average, 4.2% below the 52-week high and +112.3% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Amneal Pharmaceuticals, Inc. Class A Common Stock compare with its peers?

Against its peer group (Drug Manufacturers - Specialty & Generic · US), Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) sits 4.2% below its 52-week high, 10.2% above its 50-day average; Dr. Reddy’s Laboratories Ltd ADR (RDY) is 19.5% below, Teva Pharma Industries Ltd ADR (TEVA) is 4.1% below, Hims Hers Health Inc (HIMS) is 54.9% below. Put any of them next to AMRX in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Amneal Pharmaceuticals, Inc. Class A Common Stock trade when bond yields rise?

Over the past year Amneal Pharmaceuticals, Inc. Class A Common Stock had a beta of 0.84 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 80% of US names. On the 10 sessions in which long bonds fell most it moved −1.23% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Amneal Pharmaceuticals, Inc. Class A Common Stock do?

Amneal Pharmaceuticals develops, makes and distributes generic and specialty drugs, including injectables and biosimilars, from sites in the United States, India and Ireland. It groups its business into affordable generics, a specialty unit built around central nervous system and thyroid treatments such as Rytary and Unithroid, and a government-supply arm, AvKARE, that serves defence and veterans' health agencies. It sells through wholesalers, distributors, retail pharmacies and hospitals rather than direct to patients. The diary has no peer group listed for Amneal in our data; the comparison the market draws is with other generic-drug makers such as Viatris.

Where does Amneal Pharmaceuticals, Inc. Class A Common Stock sit in the AI build-out?

Amneal sits outside our AI build-out indices; it belongs to the healthcare sleeve of our universe, under specialty and generic drug manufacturing, with no seat in Rubin or Halo. Amneal carries no index seat, no Closelooknet score and no quotes in our editions; coverage here rests only on its chart structure, not on any scored module.

Does Amneal Pharmaceuticals, Inc. Class A Common Stock pay a dividend?

No cash distribution shows in Amneal Pharmaceuticals, Inc. Class A Common Stock’s price series over the last three years. The share count rose 5.1% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Amneal Pharmaceuticals, Inc. Class A Common Stock recently?

The most recent analyst action on Amneal Pharmaceuticals, Inc. Class A Common Stock on the Closelooknet wire is a price target by Oppenheimer on 2026-09-23 (target 27). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for AMRX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.